Toggle menu

EMERGE Biobank

Start date:
June 2013
End date:
December 2015
Co-ordinated by:
EMERGE

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

 

 Aim

To develop the infrastructure and pilot a prospective, consecutive, emergency, bioresource that will subsequently be developed for all emergency presentations

Trial Design

A pilot and feasibility programme to establish a bioresource to provide consecutive emergency samples, thus enabling investigation of the development of the acute disease/influence of disease modifiers e.g. treatment and resuscitation.

Chief Investigator

Dr Matt Reed

Local PI

Dr Matt Reed

Research Team

Paul Leonard, Sandra McGillivray, TRAK development team

Dawn Lyster, John Connolly, RIE laboratories

 

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA

Identification of Novel Psychoactive Substances (IONA)

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events